Better Early Molecular Response and relapse free survival in Newly Diagnosed Core Binding Factor Leukemia
Compared to idarubicin, GO when added to FLAG based frontline induction/consolidation regimen results in better early molecular responses and improved relapse free survival in CBF AML. Click and hear Gautam Borthakur present the new data.
ASH 2018: Safe and effective treatment of elderly patients with newly diagnosed Ph-negative ALL Katso video
In this MEDtalk John Gribben, Professor, MD DSc, Barts Cancer Institute, University of London, present the key data from MURANO study about treatment of relapsed/Refractory CLL.